Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of subjects with asthma and healthy controls

From: Differential expression of CCR2 and CX3CR1 on CD16+ monocyte subsets is associated with asthma severity

  Healthy control Asthma
Mild Moderate Severe
N 35 22 32 22
Mean, age ±SD 39 ± 12.86 39 ± 11.64 46 ± 16.1 52 ± 12.73
Gender, F|M 15|20 13|9 19|13 16|6
Asthma duration, years (mean) 18.33 16.03 21.48
Family history, n (%) 15 (68.2) 17 (53.1) 15 (68.2)
FEV% 93 77.38 69.25
History of smoking, n (%) 0 1 (4.5) 1 (3.1) 0
Current smoking, n (%) 0 3 (13.6) 3 (9.4) 2 (9.1)
SHS, n (%)   2 (9.1) 2 (6.25) 2 (9.1)
Treatment
 ICS/LABA combined inhaler
  Budesonide/formoterol (160 µg/4.5 µg)
   n (%) 0 0 23 (84.4) 15 (77.3)
   n/day    2/day 2/day
  Fluticasone/Salmeterol (125 µg/25 µg)     
   n (%) 0 0 9 (28.1) 7 (31.8)
  n/day    2/day 2/day
 SABA
  Salbutamol (200 µg)
   n (%) 0 1 (4.5) 3 (9.4) 22 (100)
   n/day   2/day 4/day 2/day
   PRN   21 (95.4) 29 (90.6) 0
 Tiotropium
  Spiriva (18 µg)
   n (%) 0 0 0 15 (68.2)
   n/day     1/day
 Montelukast
  Singulair (10 µg)
   n (%) 0 0 12 (37.5) 20 (90.9)
   n/day, course    1 course 1/day
 Anti-IgE
  Omalizumab (300 mg)
   n (%) 0 0 0 19 (86.4)
   n/month     1/month
  1. Data are presented in the form of numbers or percentage (%)
  2. FEV1 forced expiratory volume in 1 s; SHS second hand smoke; ICS inhaled corticosteroid; LABA long acting β2 agonist; SABA short acting β2 agonist; PRN as needed